Efficacy and Predictors of Short-Term First-Generation Somatostatin Analog Presurgical Treatment in Acromegaly: A Hospital-Based Study of 237 Cases.

Ming Shen,Yeping Yang,Wenqiang He,Nidan Qiao,Min He,Xuefei Shou,Meng Wang,Zengyi Ma,Zhao Ye,Yichao Zhang,Zhengyuan Chen,Qilin Zhang,Xiang Zhou,Xiaoyun Cao,Hongying Ye,Yongfei Wang,Shiqi Li,Yiming Li,Yao Zhao,Zhaoyun Zhang
DOI: https://doi.org/10.1016/j.ghir.2020.101354
IF: 2.125
2020-01-01
Growth Hormone & IGF Research
Abstract:Objective: To investigate the effectiveness and predictors of short-term somatostatin analog (SSA) presurgical therapy in a large cohort and to assess the correlation between clinical and pathological variables. Design: 237 newly diagnosed patients with acromegaly received presurgical SSA treatment for three months were recruited. Clinical characteristics were collected, and response to SSA in hormone and tumor size was evaluated. The correlation between clinical information and pathological variables were analyzed. Results: After 3 months presurgical SSA therapy, 51 (21.5%) patients were biochemically responsive with 2 cm and age 2 cm, patients with MTD 49 years than <= 49 years (48.1% and 31.0% P = 0.089). Conclusions: The baseline MTD and age correlate with granulation patterns and may be used as easily acquired predictors of presurgical SSA treatment in acromegaly. Patients over their 50s with a tumor less than 2 cm in diameter are more likely to have a response to the short-term presurgical SSA therapy.
What problem does this paper attempt to address?